Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 20Non-Muscle Invasive Bladder Neoplasms 3Hematuria 3Pain 2Carcinoma in Situ 2Urinary Bladder Neck Obstruction 1Urinary Bladder Diseases 1Urinary Bladder Calculi 1Ureteral Neoplasms 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Nephrolithiasis 1Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Lower Urinary Tract Symptoms 1Kidney Diseases 1Carcinoma, Transitional Cell 1Anxiety Disorders 1

Interventions

Mitomycin 3vofatamab 2pembrolizumab 2Nivolumab 2Gemcitabine 2Cisplatin 2B701 protein, Human herpesvirus 6 2valrubicin 1tislelizumab 1relatlimab 1enzalutamide 1enfortumab vedotin 1durvalumab 1Water 1Urinary Diversion 1Standard of Care 1Radiosurgery 1Radiation Dose Hypofractionation 1Multiparametric Magnetic Resonance Imaging 1Immunonutrition Diet 1Immune Checkpoint Inhibitors 1Gels 1Fluorouracil 1Docetaxel 1Cystoscopy 1Cystectomy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urinary Bladder Diseases × Cystoscopy × Clear all
NCT02901548 2022-07-29

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
17 enrolled 9 charts
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡